COVID-19NCT06795880
"Artificial Intelligence-Based Data Analysis Results and Mortality Prediction in Covid-19 Patients in Intensive Care"
An observational study of COVID-19, run by Kocaeli City Hospital at 1 site in Turkey (Türkiye).
Trial summary
An artificial intelligence-based analysis will be performed using retrospective data of patients treated in adult intensive care units due to COVID-19. The dataset will include various parameters such as demographic information, laboratory results, vital signs, and clinical history. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- COVID-19
- How many people
- 400 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Apr 2020to 5 Mar 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: An artificial intelligence-based analysis will be performed using retrospective data of patients treated in adult intensive care due to COVID-19.The dataset will include various parameters such as demographic information, laboratory results, vital signs, and clinical history.Among the ML models, logistic regression, support vector machines (SVM), decision trees, and deep learning techniques (e.g., artificial neural networks) will be used. The performance of the models will be compared with traditional scoring systems.
Who may be able to join
- All patients diagnosed with Covid-19 in the anesthesia and reanimation adult intensive care unit
Who cannot join
- Participants who do not meet the inclusion criteria stated above will be excluded from the study.
Trial locations and contacts
1 site in 1 country.
About this study
An artificial intelligence-based analysis will be performed using retrospective data of patients treated in adult intensive care units due to COVID-19. The dataset will include various parameters such as demographic information, laboratory results, vital signs, and clinical history. Among the machine learning models, logistic regression, support vector machines (SVM), decision trees, and deep learning techniques (e.g., artificial neural networks) will be utilized. The performance of these models will be compared with traditional scoring systems.
As a result of the analysis, it is anticipated that AI-based models will provide higher accuracy and reliability in mortality prediction. In particular, it is expected that deep learning-based models will better capture complex relationships and predict the outcomes of critically ill patients with greater precision. AI-supported data analysis results have the potential to guide diagnosis and treatment strategies in high-risk intensive care patients and can contribute to mortality prediction. AI-based approaches in intensive care are likely to offer significant advantages in the management of critical diseases such as COVID-19. These methods have the potential to improve clinical decision-making processes by providing healthcare professionals with more precise and timely information.
Read the detailed description
In this research, patient information obtained through retrospective archive scanning in high-risk patients followed up in the Anesthesia Intensive Care Unit with a diagnosis of COVID-19 will be recorded, and data analysis will be performed using artificial intelligence-based machine learning methods. The applicability of the obtained results in predicting the morbidity and mortality of patients, as well as the accuracy and reliability of these data, will be discussed.
The COVID-19 pandemic has strained healthcare systems worldwide, creating significant challenges in the management of critically ill patients, particularly in adult anesthesia intensive care units. During this process, accurately predicting the morbidity and mortality risks of patients is essential for the effective use of healthcare resources and the improvement of patient care. Traditional mortality prediction methods are generally based on clinical scoring systems and manual analysis of patient data. However, the accuracy and reliability of these methods remain limited. Artificial intelligence (AI) and machine learning (ML) techniques offer promising results in this field due to their capacity to analyze large datasets and detect complex patterns.
AI applications are used in various ways to evaluate and improve the effectiveness of intensive care treatments in COVID-19 patients. In this context, AI can be utilized in critically ill intensive care patients. Based on current information, AI can be applied to tasks such as data collection, data analysis and modeling, prognostic model development, result visualization, natural language processing (NLP), and decision support systems.
In data collection, AI algorithms can be employed to gather large and diverse datasets from hospitals quickly and accurately. This minimizes data inconsistencies and omissions, enhancing the accuracy of the study. Machine learning algorithms can analyze various variables such as patients' demographic data, disease severity, treatment protocols, and outcomes to determine the factors with the greatest impact on mortality. Algorithms such as regression models, decision trees, and random forests are commonly used for this purpose.
AI-based prognostic models can be developed using patient data to predict the most effective treatment for individual patients. These models can support optimization of treatment decisions by predicting patient responses to treatment. Furthermore, AI-powered visualization tools, such as interactive graphs and heat maps, can assist in understanding and interpreting study findings by highlighting relationships between treatment responses and mortality rates.
Natural Language Processing (NLP) can analyze unstructured data, including patient notes and medical records, to provide additional insights into treatment efficacy and side effects. This capability expands the scope of retrospective studies and enhances the accuracy of the results. AI-based decision support systems can also offer recommendations to physicians on suitable treatments for specific patient profiles, integrating clinical guidelines and the latest scientific literature.
AI-based approaches offer significant advantages in the management of critical illnesses such as COVID-19, especially in intensive care units. These methods have the potential to improve clinical decision-making by providing healthcare professionals with more precise and timely information. Additionally, AI models can quickly adapt to emerging patterns by updating themselves with new data. However, ethical and technical challenges must be addressed carefully to ensure the widespread adoption of these approaches in clinical practice.
This study aims to generate promising and informative results through data analysis performed with artificial intelligence and machine learning on the records of COVID-19 patients in intensive care. The effectiveness of AI-based machine learning methods in predicting the mortality of critically ill patients treated in intensive care due to COVID-19 will be investigated. AI-based approaches provide higher accuracy and reliability compared to traditional methods and can contribute to improved outcomes in healthcare systems. These findings may highlight the potential of artificial intelligence applications in managing future pandemics such as COVID-19 and other critical illnesses.
- Conditions
- COVID-19
- Keywords
- intensive care, machine learning, mortality
- Medical subject headings
- COVID-19
What is being measured
The primary outcome is the main question the study is designed to answer.
Mortality prediction in covid-19 patients in intensive care using artificial intelligence models
Mortality prediction in covid-19 patients in intensive care using artificial intelligence models, analysis of patient data with artificial intelligence models.
Measured: "through study completion, an average of 4 year"
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Jan 2025
- Study start1 Apr 2020
- Primary completion1 Apr 2024
- Study completion5 Mar 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for COVID-19Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Retrospective
- Enrolment
- 400 participants (actual)
Sponsor and investigators
- Lead sponsor
- Kocaeli City Hospital
- Sponsor type
- Other government
- Responsible party
- Sponsor
- Investigators
- Emine Yurt, Principal investigator, MD
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06795880
- Sponsor's protocol ID
- 2024-74
- Status last verified
- Aug 2026
- First submitted
- 24 Jan 2025
- Last updated
- 11 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Chee ML, Ong MEH, Siddiqui FJ, Zhang Z, Lim SL, Ho AFW, Liu N. Artificial Intelligence Applications for COVID-19 in Intensive Care and Emergency Settings: A Systematic Review. Int J Environ Res Public Health. 2021 Apr 29;18(9):4749. doi: 10.3390/ijerph18094749.
PubMed 33947006
Study at a glance
From the registry record, last updated by the sponsor on 11 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- "Artificial Intelligence-Based Data Analysis Results and Mortality Prediction in Covid-19 Patients in Intensive Care"
- ClinicalTrials.gov ID
- NCT06795880
- Acronym / sponsor ID
- 2024-74
- Conditions
- COVID-19
- Keywords
- intensive care, machine learning, mortality
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 400 participants (actual)
- Lead sponsor
- Kocaeli City HospitalOther government
- Study start
- 1 Apr 2020 (actual)
- Primary completion
- 1 Apr 2024 (actual)
- Study completion
- 5 Mar 2026 (actual)
- First posted
- 28 Jan 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
An artificial intelligence-based analysis will be performed using retrospective data of patients treated in adult intensive care units due to COVID-19. The dataset will include various parameters such as demographic information, laboratory results, vital signs, and clinical history. Among the machine learning models, logistic regression, support vector machines (SVM), decision trees, and deep learning techniques (e.g., artificial neural networks) will be utilized. The performance of these models will be compared with traditional scoring systems.
As a result of the analysis, it is anticipated that AI-based models will provide higher accuracy and reliability in mortality prediction. In particular, it is expected that deep learning-based models will better capture complex relationships and predict the outcomes of critically ill patients with greater precision. AI-supported data analysis results have the potential to guide diagnosis and treatment strategies in high-risk intensive care patients and can contribute to mortality prediction. AI-based approaches in intensive care are likely to offer significant advantages in the management of critical diseases such as COVID-19. These methods have the potential to improve clinical decision-making processes by providing healthcare professionals with more precise and timely information.
Detailed description
In this research, patient information obtained through retrospective archive scanning in high-risk patients followed up in the Anesthesia Intensive Care Unit with a diagnosis of COVID-19 will be recorded, and data analysis will be performed using artificial intelligence-based machine learning methods. The applicability of the obtained results in predicting the morbidity and mortality of patients, as well as the accuracy and reliability of these data, will be discussed.
The COVID-19 pandemic has strained healthcare systems worldwide, creating significant challenges in the management of critically ill patients, particularly in adult anesthesia intensive care units. During this process, accurately predicting the morbidity and mortality risks of patients is essential for the effective use of healthcare resources and the improvement of patient care. Traditional mortality prediction methods are generally based on clinical scoring systems and manual analysis of patient data. However, the accuracy and reliability of these methods remain limited. Artificial intelligence (AI) and machine learning (ML) techniques offer promising results in this field due to their capacity to analyze large datasets and detect complex patterns.
AI applications are used in various ways to evaluate and improve the effectiveness of intensive care treatments in COVID-19 patients. In this context, AI can be utilized in critically ill intensive care patients. Based on current information, AI can be applied to tasks such as data collection, data analysis and modeling, prognostic model development, result visualization, natural language processing (NLP), and decision support systems.
In data collection, AI algorithms can be employed to gather large and diverse datasets from hospitals quickly and accurately. This minimizes data inconsistencies and omissions, enhancing the accuracy of the study. Machine learning algorithms can analyze various variables such as patients' demographic data, disease severity, treatment protocols, and outcomes to determine the factors with the greatest impact on mortality. Algorithms such as regression models, decision trees, and random forests are commonly used for this purpose.
AI-based prognostic models can be developed using patient data to predict the most effective treatment for individual patients. These models can support optimization of treatment decisions by predicting patient responses to treatment. Furthermore, AI-powered visualization tools, such as interactive graphs and heat maps, can assist in understanding and interpreting study findings by highlighting relationships between treatment responses and mortality rates.
Natural Language Processing (NLP) can analyze unstructured data, including patient notes and medical records, to provide additional insights into treatment efficacy and side effects. This capability expands the scope of retrospective studies and enhances the accuracy of the results. AI-based decision support systems can also offer recommendations to physicians on suitable treatments for specific patient profiles, integrating clinical guidelines and the latest scientific literature.
AI-based approaches offer significant advantages in the management of critical illnesses such as COVID-19, especially in intensive care units. These methods have the potential to improve clinical decision-making by providing healthcare professionals with more precise and timely information. Additionally, AI models can quickly adapt to emerging patterns by updating themselves with new data. However, ethical and technical challenges must be addressed carefully to ensure the widespread adoption of these approaches in clinical practice.
This study aims to generate promising and informative results through data analysis performed with artificial intelligence and machine learning on the records of COVID-19 patients in intensive care. The effectiveness of AI-based machine learning methods in predicting the mortality of critically ill patients treated in intensive care due to COVID-19 will be investigated. AI-based approaches provide higher accuracy and reliability compared to traditional methods and can contribute to improved outcomes in healthcare systems. These findings may highlight the potential of artificial intelligence applications in managing future pandemics such as COVID-19 and other critical illnesses.
Study design
- Observational model
- Case only
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- An artificial intelligence-based analysis will be performed using retrospective data of patients treated in adult intensive care due to COVID-19.The dataset will include various parameters such as demographic information, laboratory results, vital signs, and clinical history.Among the ML models, logistic regression, support vector machines (SVM), decision trees, and deep learning techniques (e.g., artificial neural networks) will be used. The performance of the models will be compared with traditional scoring systems.
Key inclusion criteria (1 listed)
- All patients diagnosed with Covid-19 in the anesthesia and reanimation adult intensive care unit
Key exclusion criteria (1 listed)
- Participants who do not meet the inclusion criteria stated above will be excluded from the study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Mortality prediction in covid-19 patients in intensive care using artificial intelligence models
Time frame: "through study completion, an average of 4 year"
Mortality prediction in covid-19 patients in intensive care using artificial intelligence models, analysis of patient data with artificial intelligence models.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Aug 2026.
- Results publication: PubMed 33947006Chee ML, Ong MEH, Siddiqui FJ, Zhang Z, Lim SL, Ho AFW, Liu N. Artificial Intelligence Applications for COVID-19 in Intensive Care and Emergency Settings: A Systematic Review. Int J Environ Res Public Health. 2021 Apr 29;18(9):4749. doi: 10.3390/ijerph18094749.
- Improving prediction of COVID-19 mortality using machine learning in the Spanish SEMI-COVID-19 registryLink provided by the sponsor.
- Identifying Predictors of COVID-19 Mortality Using Machine LearningLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for COVID-19
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
RecruitingPhase 2
SARS-CoV-2 and Herpesvirus Inhibition for Ending Long COVID Dysfunction
Post-acute Sequelae of COVID-19, Long COVID
Active, not recruitingObservational study
A Study to Learn About COVID-19 Antivirals in People With SARS-CoV-2 Infection From 2023-2026
COVID-19 SARS-CoV-2 Infection
RecruitingPhase 4
Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study
COVID -19, COVID - 19
Enrolling by invitation
Fareon Open Label Device Clinical Trial
Cognitive Dysfunction, Acquired Brain Injury
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Emine Yurt principal investigator
MD
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of COVID-19, run by Kocaeli City Hospital at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 11 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mortality prediction in covid-19 patients in intensive care using artificial intelligence models (time frame: "through study completion, an average of 4 year"). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06795880, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Aug 2026.